BidaskClub upgraded shares of Exactech (NASDAQ:EXAC) from a sell rating to a hold rating in a report published on Monday.
EXAC has been the topic of a number of other research reports. ValuEngine cut Exactech from a buy rating to a hold rating in a research report on Friday, December 1st. Gabelli cut Exactech from a buy rating to a hold rating in a research report on Tuesday, October 24th. Zacks Investment Research upgraded Exactech from a sell rating to a hold rating in a research report on Tuesday, December 26th. Robert W. Baird set a $34.00 price target on Exactech and gave the stock a buy rating in a research report on Sunday, October 15th. Finally, Sidoti cut Exactech from a buy rating to a neutral rating in a research report on Monday, October 23rd. Six research analysts have rated the stock with a hold rating, Exactech currently has a consensus rating of Hold and a consensus price target of $49.00.
Exactech (NASDAQ EXAC) opened at $49.35 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. Exactech has a 12-month low of $23.75 and a 12-month high of $50.95. The company has a market capitalization of $711.82, a price-to-earnings ratio of 40.78, a P/E/G ratio of 3.65 and a beta of 0.90.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.